Contact Information: Contact: Matthew D. Haines Senior Director, Investor Relations and Corporate Communications (212) 209-3874 McKinney|Chicago (Media) Alan Zachary (312) 944-6784 x 316 or (708) 707-6834
MDRNA, Inc. Appoints Beverly L. Davidson, Ph.D. and Carl Novina, M.D., Ph.D., to Its Scientific Advisory Board
| Source: MDRNA, Inc.
BOTHELL, WA--(Marketwire - May 15, 2009) - MDRNA, Inc. (NASDAQ : MRNA ) announced today the
appointment of Beverly L. Davidson, Ph.D., and Carl Novina, M.D., Ph.D., to
its Scientific Advisory Board (SAB).
"The appointment of these outstanding scientists and opinion leaders to our
Scientific Advisory Board reflects our strong commitment to scientific
excellence as a premier RNAi therapeutics company," stated Barry Polisky,
Ph.D., Chief Scientific Officer. "We are particularly pleased to have
attracted these two prominent researchers, who will be instrumental in
helping us develop siRNA therapeutics and delivery systems against a broad
range of human diseases including oncology and, in particular, our liver
cancer program. During my tenure at Sirna Therapeutics, I worked with Dr.
Davidson on our SAB, and of course Dr. Novina previously served on MDRNA's
SAB during 2008."
Beverly L. Davidson, Ph.D.
Dr. Davidson is currently Professor of Medicine, Neurology and Physiology &
Biophysics in the Department of Internal Medicine at The University of
Iowa. She holds the Roy J. Carver Biomedical Research Chair and is Director
of The Davidson Laboratory, which is focused on inherited genetic diseases
that cause central nervous system dysfunction, with a focus on (1)
recessive, childhood onset neurodegenerative disease, in particular the
lysosomal storage diseases such as the mucopolysaccharidoses and Battens
disease; and (2) dominant genetic diseases for example the CAG repeat
disorders, Huntington's disease and spinal cerebellar ataxia type I, and
(3), understanding how noncoding RNAs participate in neural development and
neurodegenerative diseases processes. Dr. Davidson is a member of the
American Association for the Advancement of Science, American Federation
for Clinical Research (Midwest Section), American Society for Neuroscience,
American Society for Gene Therapy, and the American Society for
Microbiology. Dr. Davidson serves on the Board of Directors for the
American Society for Gene Therapy, and is Associate Director of the Center
for Gene Therapy for Cystic Fibrosis and other Genetic Diseases, and is
past Co-Director of the Iowa Biosciences Advantage Program.
Dr. Davidson received her Ph.D. from the University of Michigan in 1987 and
was a Fellow of the University of Michigan from 1990 to 1992.
Carl Novina, M.D., Ph.D.
Dr. Novina is an Assistant Professor in the Department of Pathology at
Harvard Medical School, an Assistant Professor of Cancer Immunology/AIDS at
Dana-Farber Cancer Institute and an Associate Member at the Broad
Institute. His research focuses on investigating the mechanisms and
applications of mammalian RNAi. To discover the biological roles of
microRNAs and their interacting proteins, his group has developed
cell-free, microRNA-dependent translational gene silencing reactions and
cell-based reporter systems for translational repression and mRNA cleavage
by microRNAs. His laboratory is engaged in collaborative projects to
profile microRNA expression as well as microRNA and RNAi factor gene loci,
in an effort to understand the roles of microRNAs in cancer, including
hematopoietic and solid tumors.
Dr. Novina received his M.D. from Columbia University, College of
Physicians and Surgeons in 2000 and his Ph.D. from Tufts University,
Sackler School of Graduate Biomedical Sciences in 1998. He did his graduate
studies on transcriptional regulation of TATA-less promoters by TFII-I in
Dr. Ananda Roy's laboratory. Dr. Novina completed his postdoctoral training
with Dr. Phillip Sharp, Nobel Laureate, at Massachusetts Institute of
Technology investigating small RNA-directed gene silencing.
Dr. Polisky added, "I am confident both Drs. Davidson and Novina will
contribute greatly to the achievement of our key scientific objectives. We
will continue to speak with and look for other prominent scientists as we
build our Scientific Advisory Board."
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health by combining novel RNAi-based compounds
and proprietary peptide- and liposomal-based drug delivery technologies to
provide superior therapeutic options. Our multi-disciplinary portfolio of
capabilities includes molecular biology, cellular biology, formulation
expertise, peptide and alkylated amino acid chemistry, pharmacology,
toxicology and bioinformatics. We are applying this expertise to a single,
integrated drug discovery platform that will be the engine for our clinical
pipeline and a versatile platform for establishing broad therapeutic
partnerships. We are also building on new technologies, such as UsiRNAs
that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA)
within the siRNA molecule, that we expect to lead to safer and more
effective RNAi-based therapeutics. By combining broad expertise in siRNA
science with proven delivery platforms and a strong and growing IP
position, MDRNA is well positioned as a leading RNAi therapeutics company
and value-added collaborator for our research partners. Additional
information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or suggested
in any forward-looking statements are contained in MDRNA's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.